Impact Genetics provides cost effective and high quality clinical genetic testing for rare diseases. Retinoblastoma (RB), Hereditary Hemorrhagic Telangiectasia (HHT), and prognostic testing for Uveal Melanoma (UM). Impact Genetics combines Retinoblastoma Solutions, HHT Solutions and Solutions by Sequence. By combining our efforts with those of leading medical, clinical, genetic and scientific experts, we build on the quality we have established, to serve additional diseases. We continue to target rare and complex diseases where our expertise will maximize sensitivity and quality. Because of Impacts’ holistic focus on disease, retinoblastoma test sensitivity has reached an unprecedented 96% in bilateral patients. As new scientific discoveries are made, sensitivity continues to increase and we believe will one day reach 100%.